Oncology Drugs - United Arab Emirates

United Arab Emirates

The United Arab Emirates is projected to witness a substantial growth in revenue within the Oncology Drugs market.
By 2024, the revenue is expected to reach US$346.60m.
Furthermore, there is an anticipated annual growth rate (CAGR 2024-2029) of 7.88%, which will contribute to a significant increase in market volume, estimated to be US$506.40m by 2029.
It is worth noting that in a global comparison, United States is expected to generate the highest revenue of US$103,900.00m in 2024.
The United Arab Emirates is witnessing a growing demand for innovative oncology drugs due to the increasing prevalence of cancer in the country.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in United Arab Emirates has been experiencing significant growth in recent years.

Customer preferences: As in many other countries, cancer is a major health concern in the United Arab Emirates, and the demand for effective oncology drugs has been steadily increasing. Patients and healthcare providers in the country are increasingly seeking out innovative treatments that can improve patient outcomes and quality of life.

Trends in the market: One of the key trends in the Oncology Drugs market in the United Arab Emirates is the growing demand for personalized medicine. This approach involves tailoring treatment to the specific genetic makeup of individual patients, which can lead to more effective and targeted therapies. Another trend is the increasing use of immunotherapy, which harnesses the power of the immune system to fight cancer cells.

Local special circumstances: The United Arab Emirates has a relatively high incidence of certain types of cancer, such as breast cancer and lung cancer. This has led to a focus on developing and distributing oncology drugs that are specifically designed to treat these types of cancer. In addition, the country has invested heavily in developing its healthcare infrastructure, which has helped to support the growth of the Oncology Drugs market.

Underlying macroeconomic factors: The United Arab Emirates has a strong and growing economy, which has helped to drive demand for oncology drugs in the country. In addition, the government has implemented policies to support the development of the healthcare sector, including investments in research and development, infrastructure, and education. Overall, these factors have contributed to the growth of the Oncology Drugs market in the United Arab Emirates.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.